Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

[1]  M. Dowsett,et al.  Predictors of response to aromatase inhibitors , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  L. Nicholson,et al.  Epigenetic Inactivation Implies Independent Functions for Insulin-like Growth Factor Binding Protein (IGFBP)-Related Protein 1 and the Related IGFBPL1 in Inhibiting Breast Cancer Phenotypes , 2007, Clinical Cancer Research.

[3]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[4]  J. Brenton,et al.  Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. , 2007, Cancer cell.

[5]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[6]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Nir Hacohen,et al.  Minimizing the risk of reporting false positives in large-scale RNAi screens , 2006, Nature Methods.

[8]  L. Lim,et al.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.

[9]  Michael C. Ostrowski,et al.  ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis , 2005, Oncogene.

[10]  R. Kumar,et al.  Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  E. McDermott,et al.  Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer , 2005, Clinical Cancer Research.

[12]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[14]  Stephen E. Jones.  A New Estrogen Receptor Antagonist – An Overview of Available Data , 2002, Breast Cancer Research and Treatment.

[15]  V. Jordan,et al.  “Studies on the estrogen receptor in breast cancer” — 20 years as a target for the treatment and prevention of cancer , 2004, Breast Cancer Research and Treatment.

[16]  M. Dowsett.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses , 2003 .

[17]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[18]  V. Laudet,et al.  The nuclear receptor superfamily , 2003, Journal of Cell Science.

[19]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[20]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .

[21]  I. Ellis,et al.  Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer , 2001, International journal of cancer.

[22]  Margaret Kasten,et al.  Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity , 2001, Oncogene.

[23]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ER a Expression in Breast Cancer Cells , 2001 .

[24]  J. Slingerland,et al.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Blamey,et al.  Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  D. Tripathy,et al.  Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .

[27]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[28]  S. Kharbanda,et al.  Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis , 1997, Oncogene.

[29]  R. Sutherland,et al.  Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[31]  J. Pouysségur,et al.  Cyclin D1 Expression Is Regulated Positively by the p42/p44MAPK and Negatively by the p38/HOGMAPK Pathway* , 1996, The Journal of Biological Chemistry.

[32]  L. Altucci,et al.  17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. , 1996, Oncogene.

[33]  Holger Karas,et al.  TRANSFAC: a database on transcription factors and their DNA binding sites , 1996, Nucleic Acids Res..

[34]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[35]  Sutherland Rl,et al.  Cell cycle control by steroid hormones. , 1994 .

[36]  R. Sutherland,et al.  Cell cycle control by steroid hormones. , 1994, Seminars in cancer biology.

[37]  P Chambon,et al.  Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. , 1984, Nucleic acids research.

[38]  W. McGuire,et al.  Studies on the estrogen receptor in breast cancer. , 1973, Advances in experimental medicine and biology.